<?xml version="1.0" encoding="UTF-8"?>
<p>Reports on the anti-inflammatory properties of glycolipid biosurfactants are few, but do suggest potential in applications that exploit these properties. Sophorolipids derived from the yeast of 
 <italic>C. bombicola</italic> reduce the lipopolysaccharide-induced expression of inflammatory cytokines [
 <xref rid="B152-pharmaceutics-12-00688" ref-type="bibr">152</xref>]. Moreover, SLs display anti-inflammatory effects in in vitro models of allergic conditions by down regulating important genes in IgE production (BSAP (Pax5), TLR-2, STAT3 and IL-6) [
 <xref rid="B153-pharmaceutics-12-00688" ref-type="bibr">153</xref>]. MELs have also been shown to inhibit the secretion of inflammatory mediators (amines such as histamine and serotonin, leukotrienes and cytokines) from mast cells [
 <xref rid="B154-pharmaceutics-12-00688" ref-type="bibr">154</xref>]. 
</p>
